To test our hypothesis that ML277 and R-L3 might serve as therapeutic agents in the treatment of some LQT-1 and LQT-5 mutation carriers, we first confirmed the efficacy of these compounds on IKS channels expressed in the absence and presence of KCNE1 subunits. This evidence concerns the gene KCNE1 and long QT syndrome 5.